April 24, 2024

Genitourinary Drugs Market Size to Garner USD 32.27 Billion by 2032

The global Genitourinary drugs market size was estimated to be around US$ 29.24 billion in 2023. It is projected to reach US$ 32.27 billion by 2032, indicating a CAGR of 1.1% from 2023 to 2032.

Genitourinary Drugs Market Size 2023 To 2032

Key Takeaways

  • North America contributed more than 49% of revenue share in 2022.
  • Asia-Pacific is estimated to witness the fastest CAGR between 2023 and 2032.
  • By indication, the prostate cancer segment held the largest market share of 28% in 2022.
  • By indication, the cervical cancer segment is anticipated to grow at a remarkable CAGR of 2.5% between 2023 and 2032.
  • By product, the hormonal therapy segment generated over 38% of revenue share in 2022.
  • By product, the gynecological segment is expected to expand at the fastest CAGR over the projected period.

The market research report on the Genitourinary drugs market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Genitourinary drugs products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.

Get a Sample: https://www.precedenceresearch.com/sample/3644 

Genitourinary Drugs Market Scope

Report Coverage Details
Market Size in 2023 USD 29.24 Billion
Market Size by 2032 USD 32.27 Billion
Growth Rate from 2023 to 2032 CAGR of 1.1%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Indication and By Product
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Colorectal Cancer Therapeutics Market Size to Garner USD 18.25 Billion by 2032

The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.

Focusing on the global Genitourinary drugs market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Genitourinary drugs market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.

Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Genitourinary drugs products across different countries and applications.

Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.

The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.

This in-depth research report offers valuable insights into the Genitourinary drugs market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.

The competitive landscape section of the report provides detailed information on Genitourinary drugs market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Genitourinary drugs market.

Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report

Reasons to Purchase this Report:

  • Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
  • In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
  • Market size in USD million and volume in million units provided for each segment and sub-segment.
  • Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
  • Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Recent Developments

  • In April 2023, GSK plc reported encouraging results from the EAGLE-2 and EAGLE-3 clinical trials for gepotidacin. The positive outcome in Phase III trials positions gepotidacin as a potential breakthrough, being the first orally administered antibiotic in its class for treating uncomplicated urinary tract infections (uUTI) in female adolescents and adults.
  • In March 2023, Pfizer Inc. disclosed its definitive merger agreement with Seagen Inc., a biotechnology firm known for its innovation in cancer medicines and expertise in antibody-drug conjugate (ADC) technology. This strategic collaboration marks a significant development in Pfizer’s pursuit of advancements in cancer treatment and underscores Seagen’s valued position in the field.

Genitourinary Drugs Market Players

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited

Segments Covered in the Report

By Indication

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Haematuria
  • Benign Prostatic Hyperplasia

By Product

  • Urologicals
  • Hormonal Therapy
  • Gynecological
  • Anti-infectives
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genitourinary Drugs Market 

5.1. COVID-19 Landscape: Genitourinary Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genitourinary Drugs Market, By Indication

8.1. Genitourinary Drugs Market Revenue and Volume, by Indication, 2023-2032

8.1.1. Prostate Cancer

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Ovarian Cancer

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Bladder Cancer

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Renal Cancer

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Erectile Dysfunction

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

8.1.7. Urinary Tract Infections

8.1.7.1. Market Revenue and Volume Forecast (2020-2032)

8.1.8. Urinary Incontinence & Overactive Bladder

8.1.8.1. Market Revenue and Volume Forecast (2020-2032)

8.1.9. Sexually Transmitted Diseases

8.1.9.1. Market Revenue and Volume Forecast (2020-2032)

8.1.10. Interstitial Cystitis

8.1.10.1. Market Revenue and Volume Forecast (2020-2032)

8.1.11. Haematuria

8.1.11.1. Market Revenue and Volume Forecast (2020-2032)

8.1.12. Benign Prostatic Hyperplasia

8.1.12.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Genitourinary Drugs Market, By Product

9.1. Genitourinary Drugs Market Revenue and Volume, by Product, 2023-2032

9.1.1. Urologicals

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Hormonal Therapy

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Gynecological

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

9.1.4. Anti-infectives

9.1.4.1. Market Revenue and Volume Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Genitourinary Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

Chapter 11. Company Profiles

11.1. GlaxoSmithKline

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. AstraZeneca

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. CytoSorbents Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cardinal Health

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Asahi Kasei

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. ConvaTec

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. CHIESI Farmaceutici

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Smith & Nephew

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *